The hypertension specialist’s perspective: aldosterone synthase inhibitors to fill the gap in difficult-to-control and resistant hypertension
American Journal of Hypertension · 2026
DOI: 10.1093/ajh/hpag083 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hypertension, 2026. Verfasst von Romina Ruth Diaz und 2 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Hypertension, Cytochrome P-450 CYP11B2, Antihypertensive Agents, Blood Pressure. Die Arbeit nennt 59 Literaturangaben. Gefördert von: German Heart Foundation, German Foundation of Heart Research, German Research Foundation.
Abstract (Originalsprache)
Aldosterone dysregulation is a key driver of difficult-to-control and resistant hypertension. Mineralocorticoid receptor antagonists (MRAs) target the aldosterone pathway but their use can be limited by side effects, particularly hyperkalemia and antiandrogenic hormonal effects. Selective aldosterone synthase inhibitors (ASIs) have shown clinically meaningful blood pressure reductions in patients with difficult-to-control and resistant hypertension in recent phase 2b and 3 trials. In this narrative review, we summarize pivotal evidence from phase 2b and phase 3 trials of the second-generation ASIs lorundrostat, baxdrostat, and dexfadrostat, reporting efficacy and core safety signals (hyperkalemia, hyponatremia, and an early functional reduction in estimated glomerular filtration rate (eGFR]). We further discuss the implications of these findings, economic and access considerations, remaining evidence gaps, future research directions, and potential practical treatment algorithms. ASIs offer clinically significant blood pressure lowering with moderate side effects when added on top of current therapies in short-term trials, though long-term outcome data are lacking. In May 2026, the US Food and Drug Administration (FDA) approved the first ASI, baxdrostat, for hypertension treatment in combination with other antihypertensive drugs in inadequately controlled adults. However, gaps remain, most notably the absence of comparative effectiveness trials versus MRAs, the standard fourth-line agent. ASIs target upstream aldosterone production and may offer a distinct, complementary role for patients with intolerance or contraindications for MRA or insufficient response. ASIs may be best reserved for the treatment of uncontrolled or resistant hypertension in combination with other antihypertensives and where MRAs are contraindicated, poorly tolerated, or insufficient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The George Institute for Global Health, Sydney, NSW, Australia.
- School of Population Health, University of New South Wales, Sydney, NSW, Australia.
- Programa de Prevención Cardiovascular, Lezica Instituto Cardiovascular, San Isidro, Argentina.
- Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany.
- German Center for Cardiovascular Research (DZHK), Partner Site North, Hamburg, Germany.
ORCID-Profile: Romina Ruth Diaz, Amelie H Ohlrogge, Aletta E Schutte
Förderung
- German Heart Foundation
- German Foundation of Heart Research
- German Research Foundation
Zitieren
APA
Diaz, R. R., Ohlrogge, A. H., & Schutte, A. E. (2026). The hypertension specialist’s perspective: aldosterone synthase inhibitors to fill the gap in difficult-to-control and resistant hypertension. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpag083
Vancouver
Diaz RR, Ohlrogge AH, Schutte AE. The hypertension specialist’s perspective: aldosterone synthase inhibitors to fill the gap in difficult-to-control and resistant hypertension. American Journal of Hypertension. 2026. doi:10.1093/ajh/hpag083
BibTeX
@article{Diaz2026,
author = {Diaz, Romina Ruth and Ohlrogge, Amelie H and Schutte, Aletta E},
title = {The hypertension specialist’s perspective: aldosterone synthase inhibitors to fill the gap in difficult-to-control and resistant hypertension},
journal = {American Journal of Hypertension},
year = {2026},
doi = {10.1093/ajh/hpag083}
}
EUVIMED